FDA Reshapes Drug Testing Approach - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA Reshapes Drug Testing Approach

The agency outlined early regulatory actions supporting nonanimal methods, including draft guidance, artificial intelligence tools, and expanded use of human-relevant data models.

  • By

  • Kathryn Wighton

  • April 20, 2026

  • 2 min

Share

  • 1

    The FDA is implementing a roadmap to reduce animal testing in drug development by 2025, meeting initial milestones.

  • 2

    Alternative methods, such as in vitro systems and computational modeling, are being advanced to improve drug testing accuracy.

  • 3

    Over 90% of drugs deemed safe in animal studies fail during human trials due to safety or efficacy issues.

  • 4

    The FDA has issued guidance to eliminate nonhuman primate testing and reduce horseshoe crab-derived endotoxin testing.

  • 5

    Collaboration with international regulators and NIH supports the FDA's efforts to improve drug safety predictions and reduce animal use.

Original Source(s)

FDA Reshapes Drug Testing Approach

  • by Kathryn Wighton

  • April 20, 2026

Related Content

Misleading AI summaries may alter recall

Participants exposed to inaccurate postevent summaries were less likely to correctly remember key details from videos they had previously watched.

Sugar may worsen antibiotic-induced gut dysbiosis

The effect was most apparent with added sugars and formulated nutritional drinks, including sports drinks and nutritional shakes.

Vitamin D may ease cancer treatment skin toxicity

Most patients reported symptom relief within 10 days, while 73% continued anticancer therapy without interruption.